Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed · Phase 2

Conditions studied: Acute Lymphoblastic Leukemia, Lymphoma, Lymphoblastic

In brief

The main purpose of this study is to find out how well participants with relapsed or refractory ALL respond to treatment with an etoposide- and teniposide-based induction chemotherapy regimen and what the side effects are. Primary Objectives: * To estimate the response rate for patients with refractory or relapsed ALL. * To estimate the survival rate of patients with refractory or relapsed ALL treated with risk-directed therapy.

Key facts

Study ID

NCT00186875

Run by

St. Jude Children's Research Hospital

People needed

47

Starts

2003-11-01

Expected to finish

2016-08-01

Last updated by the study team

2017-07-28

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Childhood ALL in first relapse OR in first hematological relapse after an extramedullary relapse, OR not attaining a complete remission with frontline therapies, OR lymphoblastic leukemia in first relapse.
• Patients must be 21 years of age or younger
• Informed consent explained to and signed by parent/legal guardian.

You may not qualify if…

• Life expectancy less than 8 weeks
• Patients with mature B cell ALL

Where it is running

• Rady Children's Hospital and Health Center — San Diego, California, United States
• St. Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.